Phase II, open-label, multi-centre study of TP300 as a single agent as first line therapy in patients with advanced gastric cancer or gastroeosophageal junction adenocarcinoma.
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2017
At a glance
- Drugs TP 300 (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors Chugai Pharma Europe
- 20 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by UKCRN.
- 25 Nov 2010 New trial record